Researchers create World’s first ibuprofen patch – delivering pain relief directly through skin

Dec 9, 2015

Researchers at the University of Warwick have worked with Coventry-based Medherant, a Warwick spinout company, to produce and patent the World’s first ever ibuprofen patch delivering the drug directly through skin to exactly where it is needed at a consistent dose rate.

They have invented a transparent adhesive patch that can consistently deliver a prolonged high dose of the painkiller ibuprofen directly through the skin. The University of Warwick researchers and Medherant have found a way to incoporate significant amounts of the drug (up to 30% weight) into the polymer matrix that sticks the patch to the patient’s skin with the drug then being delivered at a steady rate over up to 12 hours. This opens the way for the development of a range of novel long-acting over-the-counter pain relief products which can be used to treat common painful conditions like chronic back pain, neuralgia and arthritis without the need to take potentially damaging doses of the drug orally. Although there are a number of popular ibuprofen gels available these make it difficult to control dosage and are inconvenient to apply.

This novel patch incorporates polymer technology developed by the global adhesive company Bostik and exclusively licensed for transdermal use to Medherant.

Continue reading this article by clicking the name of the source below.

One comment on “Researchers create World’s first ibuprofen patch – delivering pain relief directly through skin”

  • @OP – Researchers at the University of Warwick have worked with Coventry-based Medherant, a Warwick spinout company, to produce and patent the World’s first ever ibuprofen patch delivering the drug directly through skin to exactly where it is needed at a consistent dose rate.

    Let’s hope this is honestly marketed, rather than the big-pharma stunt in Australia!

    http://www.bbc.co.uk/news/business-35090087
    The UK maker of the Nurofen “specific pain” range of products has defended their packaging, after an Australian court ordered the products off shelves.

    It said the UK-based Reckitt Benckiser had misled consumers.

    The court said products marketed to treat specific pains, such as migraine, were identical to one another.

    The products affected by the Australian court order include Nurofen Back Pain, Nurofen Period Pain, Nurofen Migraine Pain and Nurofen Tension Headache.

    The ACCC said the court had found that the firm had “engaged in misleading conduct in contravention of the Australian consumer law by representing that its Nurofen Specific Pain products were each formulated to treat a specific type of pain, when the products are identical”.

    Each product contained the same active ingredient, ibuprofen lysine 342mg.

    And the ACCC said the products were found to be “no more effective at treating the type of pain described on its packaging than any of the other Nurofen specific pain products”.

    *ACCC research also found the products were sold for almost double the price of Nurofen’s standard product*.

    The Federal Court of Australia said the products must be taken off Australian shelves within three months.



    Report abuse

Leave a Reply

View our comment policy.